On March 26, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois (Press release, Innate Pharma, MAR 26, 2025, View Source [SID1234651496]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition, Jonathan Dickinson, CEO of Innate Parma, will present in a showcase session at the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event, to give an update on Innate’s pipeline and strategy.
Presentation details
AACR 2025 ANNUAL MEETING
IPH4502, a differentiated Nectin-4 exatecan antibody-drug conjugate
Abstract Number: 5443
Session Type: Poster session
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 3
Session Date/Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM
More information can be found on the AACR (Free AACR Whitepaper) website.
AACR ONCOLOGY INDUSTRY PARTNERING EVENT
Showcase Session 2 | W192
Presenter: Jonathan Dickinson, Chief Executive Officer
Date and Time: Thursday Apr 24, 2025 4:50 PM
Location: McCormick Place Convention Center West Building, Chicago, Illinois
More information can be found on the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event website.
About IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer.
IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial includes a dose escalation part 1 and a dose optimization part 2 and will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.
In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs.